ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.

ABSTRACT: Group 2 innate lymphoid cells (ILC2s) regulate inflammation and immunity in mammalian tissues^1,2. Although ILC2s are found in cancers of these tissues³, their roles in cancer immunity and immunotherapy are unclear. Here we show that ILC2s infiltrate pancreatic ductal adenocarcinomas (PDACs) to activate tissue-specific tumour immunity. Interleukin-33 (IL33) activates tumour ILC2s (TILC2s) and CD8⁺ T cells in orthotopic pancreatic tumours but not heterotopic skin tumours in mice to restrict pancreas-specific tumour growth. Resting and activated TILC2s express the inhibitory checkpoint receptor PD-1. Antibody-mediated PD-1 blockade relieves ILC2 cell-intrinsic PD-1 inhibition to expand TILC2s, augment anti-tumour immunity, and enhance tumour control, identifyi

SUBMITTER: Moral JA 

PROVIDER: S-EPMC7060130 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature